Users Coming Off Slimming Injections Regain Weight at a Quadrupled Rate Than Those on Conventional Diets

Fresh analysis reveals that people who discontinue popular GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who stop traditional diet and exercise regimens.

Findings released in a leading health publication demonstrates that while obese individuals frequently drop about a fifth of their body weight while on the medication, the weight returns at an average rate of 0.8 kg per month after stopping.

"People buying such drugs should be aware of the risk of quick rebound weight gain when the treatment is stopped," stated expert Dr. Susan Jebb.

This pace of recovery implies a return to starting weight within about 18 months.

Analyzing Treatments

The research, which examined 37 of trials involving thousands of patients, contrasted the effects of GLP-1 agonists with older methods.

Scientists note that people who lose weight through diet and exercise usually see a more gradual creep back—perhaps 100 grams monthly—once they finish.

Understanding the Rapid Rebound

Nutrition scientists believe the mode of action of the injections accounts for the accelerated weight return.

GLP-1 drugs imitate a natural hormone called GLP-1, which helps regulate appetite.

"Sustained high doses of GLP-1 levels several times higher than normal might result in the body to generate a reduced amount of its own natural hormone, and could diminish sensitivity to its effects," explained Dr. Adam Collins, a dietetics specialist.

"Withdrawal of this hormone supplement means appetite is unsuppressed, making binge eating a significant risk."

A Chronic Condition?

The NHS advise the jabs for people with weight-linked health risks, accompanied by recommended lifestyle changes.

Professionals say that, considering the likelihood of relapse, the treatment is often life-long.

This view is reinforced by drug manufacturers, who say that the results "underscore the long-term character of obesity," akin to managing conditions like hypertension.

Patient Accounts

Individuals who have discontinued the medication explain a intense resurgence of cravings.

"It was like something flipping and you're instantly starving," said an individual.

This challenge is compounded if individuals have not adopted permanent dietary or behavioural modifications during therapy.

Significant Use

Figures show that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with interest remaining high.

• Use is more common among women than males.
• The middle-aged age group shows the greatest level of interest.
• Many obtain the medications through private healthcare rather than public health services.

Ultimately, researchers emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a magic solution and maintained weight loss likely depends on combined behavioural management.